Uncategorized Inotek Pharmaceuticals Initiates Dosing of MATRx-1, the First Pivotal Phase 3 Clinical Trial of Trabodenoson, a Novel Treatment for Glaucoma by Business Wire • 2015/10/16 • 0 Comments LEXINGTON, Mass.--(BUSINESS WIRE)--Inotek Pharmaceuticals Initiates Dosing of MATRx- 1, the First Pivotal Phase 3 Clinical Trial of Trabodenoson, a Novel Treatment for Glaucoma Full Story →